Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 138

1.

The Notch Pathway Promotes Osteosarcoma Progression through Activation of Ephrin Reverse Signaling.

Yu L, Xia K, Gao T, Chen J, Zhang Z, Sun X, Simoes BM, Eyre R, Fan Z, Guo W, Clarke RB.

Mol Cancer Res. 2019 Sep 30. pii: molcanres.0493.2019. doi: 10.1158/1541-7786.MCR-19-0493. [Epub ahead of print]

PMID:
31570655
2.

The Milk Protein Alpha-Casein Suppresses Triple Negative Breast Cancer Stem Cell Activity Via STAT and HIF-1alpha Signalling Pathways in Breast Cancer Cells and Fibroblasts.

Garner KEL, Hull NJ, Sims AH, Lamb R, Clarke RB.

J Mammary Gland Biol Neoplasia. 2019 Sep;24(3):245-256. doi: 10.1007/s10911-019-09435-1. Epub 2019 Sep 12.

PMID:
31529195
3.

PAK4 regulates stemness and progression in endocrine resistant ER-positive metastatic breast cancer.

Santiago-Gómez A, Kedward T, Simões BM, Dragoni I, NicAmhlaoibh R, Trivier E, Sabin V, Gee JM, Sims AH, Howell SJ, Clarke RB.

Cancer Lett. 2019 Aug 28;458:66-75. doi: 10.1016/j.canlet.2019.05.014. Epub 2019 May 20.

4.

Targeting Endometrial Cancer Stem Cell Activity with Metformin Is Inhibited by Patient-Derived Adipocyte-Secreted Factors.

Kitson SJ, Rosser M, Fischer DP, Marshall KM, Clarke RB, Crosbie EJ.

Cancers (Basel). 2019 May 11;11(5). pii: E653. doi: 10.3390/cancers11050653.

5.

FKBPL and its peptide derivatives inhibit endocrine therapy resistant cancer stem cells and breast cancer metastasis by downregulating DLL4 and Notch4.

McClements L, Annett S, Yakkundi A, O'Rourke M, Valentine A, Moustafa N, Alqudah A, Simões BM, Furlong F, Short A, McIntosh SA, McCarthy HO, Clarke RB, Robson T.

BMC Cancer. 2019 Apr 11;19(1):351. doi: 10.1186/s12885-019-5500-0.

6.

Estrogenicity of essential oils is not required to relieve symptoms of urogenital atrophy in breast cancer survivors.

Simões BM, Kohler B, Clarke RB, Stringer J, Novak-Frazer L, Young K, Rautemaa-Richardson R, Zucchini G, Armstrong A, Howell SJ.

Ther Adv Med Oncol. 2018 Apr 2;10:1758835918766189. doi: 10.1177/1758835918766189. eCollection 2018.

7.

The Role of Steroid Hormones in Breast and Effects on Cancer Stem Cells.

Alferez DG, Simões BM, Howell SJ, Clarke RB.

Curr Stem Cell Rep. 2018;4(1):81-94. doi: 10.1007/s40778-018-0114-z. Epub 2018 Mar 13. Review.

8.

Ethnicity influences breast cancer stem cells' drug resistance.

Kamal M, Nafie EHO, Elsers S, Alanwar S, Ibrahim R, Farag F, Mlees M, Simões BM, Spence K, Santiago-Gómez A, Salem ML, Clarke RB.

Breast J. 2018 Jul;24(4):701-703. doi: 10.1111/tbj.13021. Epub 2018 Mar 2. No abstract available.

PMID:
29498455
9.

Acquired Resistance of ER-Positive Breast Cancer to Endocrine Treatment Confers an Adaptive Sensitivity to TRAIL through Posttranslational Downregulation of c-FLIP.

Piggott L, Silva A, Robinson T, Santiago-Gómez A, Simões BM, Becker M, Fichtner I, Andera L, Young P, Morris C, Barrett-Lee P, Alchami F, Piva M, Vivanco MD, Clarke RB, Gee J, Clarkson R.

Clin Cancer Res. 2018 May 15;24(10):2452-2463. doi: 10.1158/1078-0432.CCR-17-1381. Epub 2018 Jan 23.

10.

G Protein-Coupled Receptors at the Crossroad between Physiologic and Pathologic Angiogenesis: Old Paradigms and Emerging Concepts.

De Francesco EM, Sotgia F, Clarke RB, Lisanti MP, Maggiolini M.

Int J Mol Sci. 2017 Dec 14;18(12). pii: E2713. doi: 10.3390/ijms18122713. Review.

11.

GPER mediates the angiocrine actions induced by IGF1 through the HIF-1α/VEGF pathway in the breast tumor microenvironment.

De Francesco EM, Sims AH, Maggiolini M, Sotgia F, Lisanti MP, Clarke RB.

Breast Cancer Res. 2017 Dec 6;19(1):129. doi: 10.1186/s13058-017-0923-5.

12.

Interrogating open issues in cancer medicine with patient-derived xenografts.

Byrne AT, Alférez DG, Amant F, Annibali D, Arribas J, Biankin AV, Bruna A, Budinská E, Caldas C, Chang DK, Clarke RB, Clevers H, Coukos G, Dangles-Marie V, Eckhardt SG, Gonzalez-Suarez E, Hermans E, Hidalgo M, Jarzabek MA, de Jong S, Jonkers J, Kemper K, Lanfrancone L, Mælandsmo GM, Marangoni E, Marine JC, Medico E, Norum JH, Palmer HG, Peeper DS, Pelicci PG, Piris-Gimenez A, Roman-Roman S, Rueda OM, Seoane J, Serra V, Soucek L, Vanhecke D, Villanueva A, Vinolo E, Bertotti A, Trusolino L.

Nat Rev Cancer. 2017 Sep 15;17(10):632. doi: 10.1038/nrc.2017.85. [Epub ahead of print]

PMID:
28912576
13.

Interrogating open issues in cancer precision medicine with patient-derived xenografts.

Byrne AT, Alférez DG, Amant F, Annibali D, Arribas J, Biankin AV, Bruna A, Budinská E, Caldas C, Chang DK, Clarke RB, Clevers H, Coukos G, Dangles-Marie V, Eckhardt SG, Gonzalez-Suarez E, Hermans E, Hidalgo M, Jarzabek MA, de Jong S, Jonkers J, Kemper K, Lanfrancone L, Mælandsmo GM, Marangoni E, Marine JC, Medico E, Norum JH, Palmer HG, Peeper DS, Pelicci PG, Piris-Gimenez A, Roman-Roman S, Rueda OM, Seoane J, Serra V, Soucek L, Vanhecke D, Villanueva A, Vinolo E, Bertotti A, Trusolino L.

Nat Rev Cancer. 2017 Apr;17(4):254-268. doi: 10.1038/nrc.2016.140. Epub 2017 Jan 20. Review. Erratum in: Nat Rev Cancer. 2017 Sep 15;:.

14.

Patient-derived xenograft (PDX) models in basic and translational breast cancer research.

Dobrolecki LE, Airhart SD, Alferez DG, Aparicio S, Behbod F, Bentires-Alj M, Brisken C, Bult CJ, Cai S, Clarke RB, Dowst H, Ellis MJ, Gonzalez-Suarez E, Iggo RD, Kabos P, Li S, Lindeman GJ, Marangoni E, McCoy A, Meric-Bernstam F, Piwnica-Worms H, Poupon MF, Reis-Filho J, Sartorius CA, Scabia V, Sflomos G, Tu Y, Vaillant F, Visvader JE, Welm A, Wicha MS, Lewis MT.

Cancer Metastasis Rev. 2016 Dec;35(4):547-573. doi: 10.1007/s10555-016-9653-x. Review.

15.

Complexity galore: 3D cultures, biomechanics and systems medicine at the eighth ENBDC workshop "Methods in Mammary Gland Development and Cancer".

Lloyd-Lewis B, van de Moosdijk AA, Bentires-Alj M, Clarke RB, van Amerongen R.

Breast Cancer Res. 2016 Nov 25;18(1):115.

16.

Erratum to: Patient-Derived Mammosphere and Xenograft Tumour Initiation Correlates with Progression to Metastasis.

Eyre R, Alférez DG, Spence K, Kamal M, Shaw FL, Simões BM, Santiago-Gómez A, Sarmiento-Castro A, Bramley M, Absar M, Saad Z, Chatterjee S, Kirwan C, Gandhi A, Armstrong AC, Wardley AM, O'Brien CS, Farnie G, Howell SJ, Clarke RB.

J Mammary Gland Biol Neoplasia. 2016 Dec;21(3-4):111. No abstract available.

PMID:
27815673
17.

Patient-derived Mammosphere and Xenograft Tumour Initiation Correlates with Progression to Metastasis.

Eyre R, Alférez DG, Spence K, Kamal M, Shaw FL, Simões BM, Santiago-Gómez A, Sarmiento-Castro A, Bramley M, Absar M, Saad Z, Chatterjee S, Kirwan C, Gandhi A, Armstrong AC, Wardley AM, O'Brien CS, Farnie G, Howell SJ, Clarke RB.

J Mammary Gland Biol Neoplasia. 2016 Dec;21(3-4):99-109. Epub 2016 Sep 28. Erratum in: J Mammary Gland Biol Neoplasia. 2016 Dec;21(3-4):111.

18.

SPRY1 regulates mammary epithelial morphogenesis by modulating EGFR-dependent stromal paracrine signaling and ECM remodeling.

Koledova Z, Zhang X, Streuli C, Clarke RB, Klein OD, Werb Z, Lu P.

Proc Natl Acad Sci U S A. 2016 Sep 27;113(39):E5731-40. doi: 10.1073/pnas.1611532113. Epub 2016 Sep 12.

19.

Intermittent energy restriction induces changes in breast gene expression and systemic metabolism.

Harvie MN, Sims AH, Pegington M, Spence K, Mitchell A, Vaughan AA, Allwood JW, Xu Y, Rattray NJ, Goodacre R, Evans DG, Mitchell E, McMullen D, Clarke RB, Howell A.

Breast Cancer Res. 2016 May 28;18(1):57. doi: 10.1186/s13058-016-0714-4.

20.

Cisplatin selects for stem-like cells in osteosarcoma by activating Notch signaling.

Yu L, Fan Z, Fang S, Yang J, Gao T, Simões BM, Eyre R, Guo W, Clarke RB.

Oncotarget. 2016 May 31;7(22):33055-68. doi: 10.18632/oncotarget.8849.

21.

A Role for Notch Signalling in Breast Cancer and Endocrine Resistance.

Acar A, Simões BM, Clarke RB, Brennan K.

Stem Cells Int. 2016;2016:2498764. doi: 10.1155/2016/2498764. Epub 2016 Jan 10. Review.

22.

Multifunctionalized iron oxide nanoparticles for selective drug delivery to CD44-positive cancer cells.

Aires A, Ocampo SM, Simões BM, Josefa Rodríguez M, Cadenas JF, Couleaud P, Spence K, Latorre A, Miranda R, Somoza Á, Clarke RB, Carrascosa JL, Cortajarena AL.

Nanotechnology. 2016 Feb 12;27(6):065103. doi: 10.1088/0957-4484/27/6/065103. Epub 2016 Jan 12.

PMID:
26754042
23.

Involvement of Inhibitory Receptors in Modulating Dopamine Signaling and Synaptic Activity Following Acute Ethanol Exposure in Striatal Subregions.

Clarke RB, Söderpalm B, Lotfi A, Ericson M, Adermark L.

Alcohol Clin Exp Res. 2015 Dec;39(12):2364-74. doi: 10.1111/acer.12895. Epub 2015 Nov 28.

PMID:
26614538
24.

An integrated genomic approach identifies that the PI3K/AKT/FOXO pathway is involved in breast cancer tumor initiation.

Smit L, Berns K, Spence K, Ryder WD, Zeps N, Madiredjo M, Beijersbergen R, Bernards R, Clarke RB.

Oncotarget. 2016 Jan 19;7(3):2596-610. doi: 10.18632/oncotarget.6354.

25.

Leptin as a mediator of tumor-stromal interactions promotes breast cancer stem cell activity.

Giordano C, Chemi F, Panza S, Barone I, Bonofiglio D, Lanzino M, Cordella A, Campana A, Hashim A, Rizza P, Leggio A, Győrffy B, Simões BM, Clarke RB, Weisz A, Catalano S, Andò S.

Oncotarget. 2016 Jan 12;7(2):1262-75. doi: 10.18632/oncotarget.6014.

26.

Anti-estrogen Resistance in Human Breast Tumors Is Driven by JAG1-NOTCH4-Dependent Cancer Stem Cell Activity.

Simões BM, O'Brien CS, Eyre R, Silva A, Yu L, Sarmiento-Castro A, Alférez DG, Spence K, Santiago-Gómez A, Chemi F, Acar A, Gandhi A, Howell A, Brennan K, Rydén L, Catalano S, Andó S, Gee J, Ucar A, Sims AH, Marangoni E, Farnie G, Landberg G, Howell SJ, Clarke RB.

Cell Rep. 2015 Sep 29;12(12):1968-77. doi: 10.1016/j.celrep.2015.08.050. Epub 2015 Sep 17.

27.

The role of steroid hormones in breast cancer stem cells.

Simões BM, Alferez DG, Howell SJ, Clarke RB.

Endocr Relat Cancer. 2015 Dec;22(6):T177-86. doi: 10.1530/ERC-15-0350. Epub 2015 Sep 17. Review.

PMID:
26381288
28.

The seventh ENBDC workshop on methods in mammary gland development and cancer.

Glukhova MA, Hynes N, Vivanco Md, van Amerongen R, Clarke RB, Bentires-Alj M.

Breast Cancer Res. 2015 Sep 2;17:119. doi: 10.1186/s13058-015-0629-5.

29.

Dissecting tumor metabolic heterogeneity: Telomerase and large cell size metabolically define a sub-population of stem-like, mitochondrial-rich, cancer cells.

Lamb R, Ozsvari B, Bonuccelli G, Smith DL, Pestell RG, Martinez-Outschoorn UE, Clarke RB, Sotgia F, Lisanti MP.

Oncotarget. 2015 Sep 8;6(26):21892-905.

30.

Doxycycline down-regulates DNA-PK and radiosensitizes tumor initiating cells: Implications for more effective radiation therapy.

Lamb R, Fiorillo M, Chadwick A, Ozsvari B, Reeves KJ, Smith DL, Clarke RB, Howell SJ, Cappello AR, Martinez-Outschoorn UE, Peiris-Pagès M, Sotgia F, Lisanti MP.

Oncotarget. 2015 Jun 10;6(16):14005-25.

31.

Risk determination and prevention of breast cancer.

Howell A, Anderson AS, Clarke RB, Duffy SW, Evans DG, Garcia-Closas M, Gescher AJ, Key TJ, Saxton JM, Harvie MN.

Breast Cancer Res. 2014 Sep 28;16(5):446. doi: 10.1186/s13058-014-0446-2. Review.

32.

Co-ordination of cell cycle, migration and stem cell-like activity in breast cancer.

Lamb R, Lisanti MP, Clarke RB, Landberg G.

Oncotarget. 2014 Sep 15;5(17):7833-42.

33.

Focal adhesion kinase and Wnt signaling regulate human ductal carcinoma in situ stem cell activity and response to radiotherapy.

Williams KE, Bundred NJ, Landberg G, Clarke RB, Farnie G.

Stem Cells. 2015 Feb;33(2):327-41. doi: 10.1002/stem.1843.

34.

Patient-derived xenograft models: an emerging platform for translational cancer research.

Hidalgo M, Amant F, Biankin AV, Budinská E, Byrne AT, Caldas C, Clarke RB, de Jong S, Jonkers J, Mælandsmo GM, Roman-Roman S, Seoane J, Trusolino L, Villanueva A.

Cancer Discov. 2014 Sep;4(9):998-1013. doi: 10.1158/2159-8290.CD-14-0001. Epub 2014 Jul 15. Review.

35.

Increase in nucleus accumbens dopamine levels following local ethanol administration is not mediated by acetaldehyde.

Clarke RB, Adermark L, Chau P, Söderpalm B, Ericson M.

Alcohol Alcohol. 2014 Sep-Oct;49(5):498-504. doi: 10.1093/alcalc/agu047. Epub 2014 Jul 25.

PMID:
25063803
36.

17β-estradiol regulates giant vesicle formation via estrogen receptor-alpha in human breast cancer cells.

Wright PK, Jones SB, Ardern N, Ward R, Clarke RB, Sotgia F, Lisanti MP, Landberg G, Lamb R.

Oncotarget. 2014 May 30;5(10):3055-65.

37.

A differential role for CXCR4 in the regulation of normal versus malignant breast stem cell activity.

Ablett MP, O'Brien CS, Sims AH, Farnie G, Clarke RB.

Oncotarget. 2014 Feb 15;5(3):599-612.

38.

P-cadherin signals through the laminin receptor α6β4 integrin to induce stem cell and invasive properties in basal-like breast cancer cells.

Vieira AF, Ribeiro AS, Dionísio MR, Sousa B, Nobre AR, Albergaria A, Santiago-Gómez A, Mendes N, Gerhard R, Schmitt F, Clarke RB, Paredes J.

Oncotarget. 2014 Feb 15;5(3):679-92.

39.

Enrichment of human osteosarcoma stem cells based on hTERT transcriptional activity.

Yu L, Liu S, Zhang C, Zhang B, Simões BM, Eyre R, Liang Y, Yan H, Wu Z, Guo W, Clarke RB.

Oncotarget. 2013 Dec;4(12):2326-38.

40.

Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer.

Eccles SA, Aboagye EO, Ali S, Anderson AS, Armes J, Berditchevski F, Blaydes JP, Brennan K, Brown NJ, Bryant HE, Bundred NJ, Burchell JM, Campbell AM, Carroll JS, Clarke RB, Coles CE, Cook GJ, Cox A, Curtin NJ, Dekker LV, Silva Idos S, Duffy SW, Easton DF, Eccles DM, Edwards DR, Edwards J, Evans D, Fenlon DF, Flanagan JM, Foster C, Gallagher WM, Garcia-Closas M, Gee JM, Gescher AJ, Goh V, Groves AM, Harvey AJ, Harvie M, Hennessy BT, Hiscox S, Holen I, Howell SJ, Howell A, Hubbard G, Hulbert-Williams N, Hunter MS, Jasani B, Jones LJ, Key TJ, Kirwan CC, Kong A, Kunkler IH, Langdon SP, Leach MO, Mann DJ, Marshall JF, Martin L, Martin SG, Macdougall JE, Miles DW, Miller WR, Morris JR, Moss SM, Mullan P, Natrajan R, O'Connor JP, O'Connor R, Palmieri C, Pharoah PD, Rakha EA, Reed E, Robinson SP, Sahai E, Saxton JM, Schmid P, Smalley MJ, Speirs V, Stein R, Stingl J, Streuli CH, Tutt AN, Velikova G, Walker RA, Watson CJ, Williams KJ, Young LS, Thompson AM.

Breast Cancer Res. 2013 Oct 1;15(5):R92. doi: 10.1186/bcr3493. Review.

41.

Lapatinib inhibits stem/progenitor proliferation in preclinical in vitro models of ductal carcinoma in situ (DCIS).

Farnie G, Johnson RL, Williams KE, Clarke RB, Bundred NJ.

Cell Cycle. 2014;13(3):418-25. doi: 10.4161/cc.27201. Epub 2013 Nov 18.

43.

Enhanced tissue regeneration potential of juvenile articular cartilage.

Liu H, Zhao Z, Clarke RB, Gao J, Garrett IR, Margerrison EE.

Am J Sports Med. 2013 Nov;41(11):2658-67. doi: 10.1177/0363546513502945. Epub 2013 Sep 16.

PMID:
24043472
44.

Recent advances reveal IL-8 signaling as a potential key to targeting breast cancer stem cells.

Singh JK, Simões BM, Howell SJ, Farnie G, Clarke RB.

Breast Cancer Res. 2013;15(4):210. Review.

45.

Targeting IL-8 signalling to inhibit breast cancer stem cell activity.

Singh JK, Simões BM, Clarke RB, Bundred NJ.

Expert Opin Ther Targets. 2013 Nov;17(11):1235-41. doi: 10.1517/14728222.2013.835398. Epub 2013 Sep 14.

PMID:
24032691
46.

Wnt pathway activity in breast cancer sub-types and stem-like cells.

Lamb R, Ablett MP, Spence K, Landberg G, Sims AH, Clarke RB.

PLoS One. 2013 Jul 4;8(7):e67811. doi: 10.1371/journal.pone.0067811. Print 2013.

47.

Cell cycle regulators cyclin D1 and CDK4/6 have estrogen receptor-dependent divergent functions in breast cancer migration and stem cell-like activity.

Lamb R, Lehn S, Rogerson L, Clarke RB, Landberg G.

Cell Cycle. 2013 Aug 1;12(15):2384-94. doi: 10.4161/cc.25403. Epub 2013 Jun 26.

48.

Targeting treatment-resistant breast cancer stem cells with FKBPL and its peptide derivative, AD-01, via the CD44 pathway.

McClements L, Yakkundi A, Papaspyropoulos A, Harrison H, Ablett MP, Jithesh PV, McKeen HD, Bennett R, Donley C, Kissenpfennig A, McIntosh S, McCarthy HO, O'Neill E, Clarke RB, Robson T.

Clin Cancer Res. 2013 Jul 15;19(14):3881-93. doi: 10.1158/1078-0432.CCR-13-0595. Epub 2013 Jun 5.

49.

Oestrogen increases the activity of oestrogen receptor negative breast cancer stem cells through paracrine EGFR and Notch signalling.

Harrison H, Simões BM, Rogerson L, Howell SJ, Landberg G, Clarke RB.

Breast Cancer Res. 2013 Mar 8;15(2):R21. doi: 10.1186/bcr3396.

50.

Combined inhibition of ErbB1/2 and Notch receptors effectively targets breast ductal carcinoma in situ (DCIS) stem/progenitor cell activity regardless of ErbB2 status.

Farnie G, Willan PM, Clarke RB, Bundred NJ.

PLoS One. 2013;8(2):e56840. doi: 10.1371/journal.pone.0056840. Epub 2013 Feb 14.

Supplemental Content

Loading ...
Support Center